Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor”

92 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 92 results

Not applicableUnknownNCT06134635
What this trial is testing

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Who this might be right for
Acute Ischemic Stroke
Xuanwu Hospital, Beijing 80
Post-approval studies (Phase 4)Study completedNCT03096288
What this trial is testing

Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

Who this might be right for
Atherosclerotic Cardiovascular Disease
University of Florida 259
Testing effectiveness (Phase 2)Study completedNCT04173793
What this trial is testing

PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Who this might be right for
Heterozygous Familial Hypercholesterolemia
Akeso 109
Testing effectiveness (Phase 2)Study completedNCT03815812
What this trial is testing

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Who this might be right for
Hypercholesterolemia
Innovent Biologics (Suzhou) Co. Ltd. 60
Post-approval studies (Phase 4)UnknownNCT05298475
What this trial is testing

Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

Who this might be right for
Acute Coronary Syndrome
The First Affiliated Hospital with Nanjing Medical University 100
Testing effectiveness (Phase 2)UnknownNCT06304987
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Beijing Friendship Hospital 50
Post-approval studies (Phase 4)Not Yet RecruitingNCT07290699
What this trial is testing

Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period

Who this might be right for
STEMI - ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Second Affiliated Hospital of Nanchang University 2,442
Post-approval studies (Phase 4)Study completedNCT04608474
What this trial is testing

Lipid Management in Renal Transplant Recipients Using Evolocumab.

Who this might be right for
Hyperlipidemias
Brigham and Women's Hospital 81
Early research (Phase 1)Study completedNCT04197817
What this trial is testing

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Who this might be right for
Hypercholesterolemia
Shanghai Junshi Bioscience Co., Ltd. 84
Post-approval studies (Phase 4)Not Yet RecruitingNCT06083961
What this trial is testing

The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile

Who this might be right for
Stroke, Acute IschemicPCSK9 Inhibitor
Sun U. Kwon 200
Post-approval studies (Phase 4)Not Yet RecruitingNCT07605130
What this trial is testing

Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter Trial

Who this might be right for
Intracranial ArteriosclerosisCognitive Impairment
Peking Union Medical College Hospital 440
Post-approval studies (Phase 4)UnknownNCT05976893
What this trial is testing

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Who this might be right for
ASCVDAtherosclerotic Cardiovascular DiseaseProprotein Convertase Subtilisin/Kexin Type 9 Inhibitor+1 more
Xiang Xie 620
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07062328
What this trial is testing

A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

Who this might be right for
Biliary Tract Carcinoma
Sun Yat-sen University 39
Large-scale testing (Phase 3)Study completedNCT06696820
What this trial is testing

Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke

Who this might be right for
Acute Ischemic Stroke
Xiang Luo 429
Post-approval studies (Phase 4)Not Yet RecruitingNCT06683131
What this trial is testing

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Who this might be right for
Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University 1,160
Testing effectiveness (Phase 2)Study completedNCT01375764
What this trial is testing

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

Who this might be right for
Hyperlipidemia
Amgen 160
Testing effectiveness (Phase 2)Study completedNCT05261126
What this trial is testing

The Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Who this might be right for
HypercholesterolemiaFamilial Hypercholesterolemia
Merck Sharp & Dohme LLC 381
Not applicableUnknownNCT06034691
What this trial is testing

Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB

Who this might be right for
Hemodialysis Access Failure
RenJi Hospital 40
Not applicableNot Yet RecruitingNCT07674524
What this trial is testing

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)HyperlipidemiaALK Gene Mutation+1 more
Sun Yat-sen University 160
Post-approval studies (Phase 4)Looking for participantsNCT05292404
What this trial is testing

Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction

Who this might be right for
Acute Myocardial Infarction
Shanghai Tong Ren Hospital 160
Next Page